LIDDS AB has signed a research agreement with a major pharmaceutical company, giving it an exclusive option right to leverage LIDDS' NanoZolid technology for the development of an injectable, controlled-release formulation for cancer treatment, the Swedish company revealed on Friday.
According to the company, the NanoZolid technology allows for a controlled, sustained and customised release of medication by releasing it locally and effectively, resulting in fewer side effects when compared with systemic treatment.
The terms of the agreement will see LIDDS conduct feasibility studies that will be fully funded by the other party. Following completion of the development work, the other party will have the right to exercise its option and enter into an exclusive agreement with LIDDS to further develop the formulation based on NanoZolid.
LIDDS CEO, Monica Wallter, said the company is committed to providing the NanoZolid technology to "enhance the performance of drugs by either reducing its side effects or facilitate longer acting pharmaceuticals to improve compliance and quality of life for its patients."
The company has several development projects in oncology, with its prostate cancer project is currently in Phase IIb trials. It also has several promising preclinical projects that see NanoZolid combined with cytotoxic drugs and with immune-active substances, such as antibodies.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval